References
- Bechgaard H. Design of controlled release products as adapted to gastrointestinal pH and transit time. Optimization of drug delivery, H. Bundgaard, A. B. Hansen, H. Kofod. Munksgaard, Copenhagen 1982; 67–77
- Bechgaard H., Chasseaud R. R., Brodie L. F., Houmøller P., Hunter J. A., Siklos P., Taylor T. Bioavailability of indomethacin from two multiple-units controlled-release formulations. Eur J Clin Pharmacol 1982; 21: 511
- Boardman P. L., Dudley Hart F. Side effects of indomethacin. Ann Rheum Dis 1967; 26: 127
- Helleberg L. Clinical pharmacokinetics of indomethacin. Clin Pharmacokinet 1981; 6: 245
- Huskisson E. C., Taylor R. T., Burston D., Chuter P. J., Dudley Hart F. Evening indomethacin in the treatment of rheumatoid arthritis. Ann Rheum Dis 1970; 29: 393
- Rothermich N. O. An extended study of indomethacin. JAMA 1966; 195: 531
- Hart A. R., Rhymem C. B., Daurio C. A double-blind trial comparing indomethacin sustained release capsules (Indocid-R) with indomethacin capsules in patients with rheumatoid arthritis. Rheumatol Rehabil 1982; 21: 101
- Statistical evaluation of clinical trials with Acetard. Spadille 1978, Internal Report, A/S Alfred Benzon